Background/Aims: gastric cancer is a serious health concern with high morbidity and mortality. Therefore, it is urgent to find novel targets for gastric cancer diagnosis and treatment. Methods: qRT-PCR and immunohistochemistry assays were used to detect GTPBP4 expression in gastric cancer tissues, and gastric cancer and gastric epithelial cells. Lentivirus infection was used to construct GTPBP4 stable knockdown cells. Annexin V/PI apoptosis, CCK8, EdU incorporation and cell clone formation analysis were performed to evaluate the effects of GTPBP4 on gastric cancer cell proliferation and apoptosis. Further RNA-based high-throughput sequencing and co-IP assays were constructed to explore the related mechanisms contributing to GTPBP4-mediated effects. Results: GTPBP4 expression was significantly increased in gastric cancer tissues compared with that in adjacent normal tissues, and positively correlated with gastric cancer stages. Meanwhile, GTPBP4 level was markedly upregulated in gastric cancer cells than in gastric epithelial cells. Additionaly, stable knockdown of GTPBP4 inhibited cell proliferation and promoted cell apoptosis. Mechanistically, p53 and its related signaling were significantly activated in GTPBP4 stable knockdown cells. And GTPBP4 interacted with p53 in gastric cancer cells. Conclusions: our results provide insights into mechanistic regulation and linkage of the GTPBP4-p53 in gastric cancer, and also a valuable potential target for gastric cancer.
GTPBP4 Promotes Gastric Cancer Progression via Regulating P53 Activity
Li
Introduction
Gastric cancer is a kind of tumor with high morbidity and mortality [1] . Although surgical treatment, chemotherapy and radiotherapy could greatly improve the survival of patients with gastric cancer, which could not be cured or recurred within several years [2] . Thus, it is very important for patients with gastric cancer to get early diagnosis and treatment, and it is an urgent need to find new targets for treating or predicting gastric cancer.
P53 has been proved to play important roles in gastric cancer progression. For example, p53 deregulation is closely associated with Epstein-Barr virus-associated gastric cancer [3] . P53 loss could drive gastric tumorigenesis [4] . On the contrary, activating p53/caspase-3 signaling could suppress gastric cancer progression [5] . Based on the critical roles of p53 in tumor progression, researchers had been investigating the mechanisms regulating p53 expression. NML-mediated rRNA base methylation links ribosomal subunit formation to cell proliferation in a p53-dependent manner [6] . During mitotic catastrophe, chromosomal breaks could trigger gammaH2AX-ATM-p53-mediated apoptosis [7] . However, the detailed mechanisms regulating p53 expression in gastric cancer are not well-defined.
Previous study investigated the protein interaction profiles of Drosophila p53 and uncovered additional nodes of human p53 network via a genome-scale assay [8] , in which GTPBP4 (guanosine triphosphate binding protein 4), also known as Nog1, was identified as an interactor and GTPBP4 knockdown induced p53 activation in the absence of nucleolar disruption. Previous study has shown that TOR regulates late steps of ribosome maturation in the nucleoplasm via GTPBP4 in response to nutrients, and GTPBP4 is required for biogenesis of the 60 S ribosomal subunit [9, 10] . Importantly, in wide-type p53 breast tumors, GTPBP4 expression is negatively correlated with patient survival, demonstrating a potential relevance of GTPBP4-p53 interaction in cancers. Recently, Yu, H et al. indicated that upregulation of GTPBP4 is responsible for colorectal tumor metastasis [11] . However, the roles of GTPBP4 and GTPBP4-p53 interaction have not been revealed in gastric cancer progression.
Here, GTPBP4 expression was meaured in gastric cancer and normal adjacent tissues, and we found that GTPBP4 expression was significantly increased in gastric cancer tissues and positively correlated with gastric cancer stages. Further GTPBP4-stable knockdown gastric cancer cells were constructed, and used to evaluate the effects of GTPBP4 in cell proliferation and apoptosis. Additionally, RNA-based high-throughput sequencing and western blot analyses were performed to explore the mechanisms contributing to GTPBP4 roles in gastric cancer.
Materials and Methods
Clinical samples and cell culture 30 pairs of gastric cancer and normal adjacent tissue samples were collected from The Affiliated Hospital of Xuzhou Medical University. Written informed consent from all patients and approval of the Hospital Ethic Review Committees were obtained. Gastric cancer cell lines MKN-45、AGS、BGC-823、MGC-803 and normal gastric epithelial cell line GES-1 were purchased from the Chinese Academy of Sciences Cell Bank. SCG7901-DDP (SCG7901 cisplatin resistant cells) and SCG7901 cells were purchased from (KeyGEN BioTECH, Nanjing, China). MKN45 and BGC-823 were cultured in Dulbecco's Minimum Essential Medium (DMEM) medium (Gibco, USA), and AGS, MGC-803, GES-1, SCG7901-DDP and SCG7901 were cultured in 1640 medium (Gibco). All medium were supplemented with 10% FBS (Fetal Bovine Serum) (Gibco), 80 U/ ml penicillin and 0.08 mg/ml streptomycin. Cells were cultured at 37°C under humidified atmosphere with 5% CO 2 .
Lentivirus plasmids and stable knockdown cell lines construction
We thanked for OBiO Inc. for constructing the knockdown lentivirus vectors of GTPBP4 (LV-GTPBP4-shRNA), ATP1B3 (LV-ATB1B3-shRNA), MLLT11 (LV-MLLT11-shRNA), CHN1 (LV-CHN1-shRNA), CORO1C (LV-CORO1C-shRNA), GAS7 (LV-GAS7-shRNA), KRT6B (LV-KRT6B-shRNA), CDCA7 (LV-CDCA7-shRNA), RFTN1 (LV-RFTN1-shRNA), DNAJB5 (LV-DNAJB5-shRNA), IL8 (LV-IL-8-shRNA), IFITM3 (LV-IFITM3-shRNA), VCL (LV-VCL-shRNA), CAP2 (LV-CAP2-shRNA), MCM8 (LV-MCM8-shRNA), TREM2 (LV-TREM2-shRNA), RERG (LV-RERG-shRNA), MNDA (LV-MNDA-shRNA), GTSF1 (LV-GTSF1-shRNA), CLIP4 (LV-CLIP4-shRNA), HECW2 (LV-HECW2-shRNA) and p53 (LV-p53-shRNA) which were verified by DNA sequencing. An empty virus was utilized as a control group in this work. Transcriptome sequencing assay Total RNA was extracted from MKN45 cells with GTPBP4 knockdown or not, and purified using HiPure kit (REF MB602-50PR, HiMedia, Mumbai, India), according to the manufacturer's instruction, and then subjected to transcriptome sequencing assay. The procedure could be referred to the manufacturer's protocol (Illumina, San Diego, USA).
High Content Screening (HCS) assay

Cell viability assay
Cell count Kit-8 (CCK-8) (Vazyme Biotech Co.,Ltd, China) was used to evaluate cell proliferation ability. Cells with GTPBP4 stable knockdown or not were seeded in 96-well plates at 4000 cells/well. After 1 -5 days, cell ability was examined. Triplicate experiments were performed for each assay.
Cell apoptosis assay
Cell apoptosis was measured using flow cytometry analysis with AnnexinV-FITC staining (Vazyme Biotech Co.,Ltd, China). Cells with GTPBP4 stable knockdown or not were harvested and washed with icecold PBS, and. then stained with Annexin V-FITC following the manufacturer's recommendation. The flow cytometry analysis was performed by flow cytometry (BD Biosciences).
Cell clone formation assay
Cell clone formation assay was used to examine cell viability. Briefly, 500 cells with GTPBP4 stable knockdown or not were seeded into 6-well plates and cultured for 11 days. Cell clones were fixed with methanol and stained with crystal violet, and then photographed with camera. The represented results were presented in results. Triplicate experiments were performed for each assay.
5-ethynyl-2'-deoxyuridine (EdU) incorporation assay
EdU incorporation assay was used to determine the speed of DNA synthesis with a keyFluor488 Click-iT EdU kit (KeyGEN BioTECH) following the manufacturer's instructions. The detailed procedure was referred to the previous study [12] . Briefly, cells were seeded in confocal dish and 50 mM EdU was added, and cultured for additional 3 h at room temperature. Then cells were fixed with 4% paraformaldehyde for 15 min. After washing with 3% BSA (Bovine Serum Albumin), cells were permeabilized with 0.5% Triton X-100 for 20 min at room temperature. After washing with 3% BSA, 500 ml Click-iT mix was added to each well, and cells were incubated for 30 min, and then cells were subsequently stained with 1 ml Hoechst 33342 for 15 min and visualized under a laser scanning confocal microscope.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cells using Trizol reagent (Invitrogen, USA) following the manufacturer's commendation. Then total RNA was reverse transcribed into cDNA using M-MLV (Promega, USA) following manufacturer's protocols. Then, mRNA expression levels were detected according to the protocols of SYBR Green Master Mix (ThermoFisher Scientific, USA), and performed on an ABI Prism 7500 Detection System (Applied Biosystems, Inc., USA). qRT-PCR primers were listed as follows: GTPBP4 forward: 5'-AGTTGCTCTCGAACTCCACG -3', reverse: 5'-TGTCTATCCGCCTCCCCTTT -3'. GAPDH was used as an internal reference. qRT-PCR primers for GAPDH were listed as follows: GAPDH forward: 5'-GCCTCAAGACCTTGGGCTGGGACTG -3', reverse: 5'-CTAAGTCCCTCCTACAAAA -3'. Then, expression of each transcript was calculated using the 2 -∆∆ct method.
Western blotting Detailed procedure was described elsewhere [13] . The antibodies against GTPBP4 (ab92342), TNFRSF10B (ab199357), MDM2 (ab16895), p53, CCND1 (ab134175), FAS (ab82419), PTEN (ab79156), CDKN1A (ab109520) and GAPDH (ab9485) were purchased from Abcam. Blots were washed and incubated with a peroxidase-conjugated antibody (R&D Systems), and chemiluminescence was detected using an enhanced chemiluminescence kit (orb90504, biorbyt) followed by exposure with Tanon 5200.
Co-immunoprecipitation (IP) assay
Total cell lysis buffer were prepared in RIPA lysis buffer with protease inhibitor. Proteins were immunoprecipitated with anti-GTPBP4 (1:100), anti-p53 (1:100) and captured by protein G magnetic beads Cellular Physiology and Biochemistry
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(Bio-rad, America) at 4°C overnight. Then the beads were washed three times using RIPA. 50 μl loading buffer were added into centrifuge tubes. All samples were analyzed using SDS-PAGE electrophoresis.
Immunohistochemistry assay
Gastric tumor and adjacent normal tissue specimens were fixed in formalin and embedded in paraffin. The detailed procedure was referred to the previous study [14] . Briefly, paraffin sections were cut to a thickness of 4 µm, and the slides were dewaxed in xylene and rehydrated with graded ethanol. A standard Tris-EDTA buffer and high pressure cooking was used for antigen retrieval and then sections were blocked in 3% H 2 O 2 in TBS and 5% BSA (bovine serum albumin). Sections were incubated with primary antibody (anti-GTPBP4 (ab92342)) over night at 4°C and then reheated at 37°C for 45 min, blotted with HRP-conjugated secondary antibody at room temperature for 1 h. After washing with PBS for three times, slides were stained with the ABC detection system following the manufacturer's recommendation.
Statistical analysis
All data were presented as mean ± SD (standard deviation). GraphPad Prism software was used to analyze the data. For three independent experiments, two-tailed of the student's t test was used to evaluate the differences between groups and *P < 0.05 or less was considered significant.
Results
GTPBP4
expression is significantly higher in gastric tumor than normal adjacent tissues Firstly, 30 pairs of gastric tumor and adjacent normal tissues were used to detect the expression of genes. RNA-based transcriptome sequencing assay showed that 20 genes expression (GTPBP4, ATP1B3, MLLT11, CHN1,  CORO1C, GAS7, KRT6B, CDCA7,  RFTN1, DNAJB5, IL8, IFITM3,  VCL, CAP2, MCM8, TREM2, RERG,  MNDA, GTSF1, CLIP4, HECW2) were significantly increased in gastric tumors compared with that in normal adjacent tissues (Fig.  1A) . Then lentivirus infection was used to knockdown these genes, and followed by further HCS assay to investigate the effects on cell proliferation ability. As shown in Fig.  1B , IL-8 and GTPBP4 knockdown exerted more efficient effects on cell viability than other genes. As the functions of IL-8 were wellknown, GTPBP4 was used to further analysis. Further qRT-PCR, western blot and immunohistochemistry assays confirmed the expression of GTPBP4 in gastric tumor and adjacent normal tissues Fig.  2A and 2B ). Then MKN45 and AGS cells with GTPBP4 knockdown or not were subjected to cell proliferation analysis via cell counting and EdU incorporation assays. As shown in Fig.  2C and 2D, knockdown of GTPBP4 significantly inhibited gastric cancer cell proliferation. Identical results were obtained via EdU incorporation assay (Fig. 3A) . Additionally, cell apoptosis assay indicated that GTPBP4 knockdown significantly promoted cell apoptosis in gastric cancer cells (Fig. 3B) , And increased the expression of apoptotic executors (cleaved caspase3 and cleaved PARP) (Fig. 3C) .
Knockdown of GTPBP4 inhibits the cloning ability of gastric cancer cells
As cell clone formation ability could greatly reflect cell viability, MKN45 and AGS cells with GTPBP4 knockdown or not were further subjected to cell clone formation assay. In consistent with cell proliferation assay, GTPBP4 knockdown remarkably suppressed cell clone formation in MKN45 and AGS cells (Fig. 4A and 4B) . Thus, these results demonstrate that 
P53-related signaling is engaged in GTPBP4 functions in gastric cancer
To further explore the detailed mechanisms contributing to GTPBP4 functions in gastric cancer, MKN45 cells with GTPBP4 knockdown or not were used for transcriptome sequencing assay. We found that p53 expression was markedly increased in GTPBP4 knockdown cells (Fig. 5A) , while the downstream negative effectors of p53 (PTEN, CDKN1A, TNFRSF10B) were downregulated with GTPBP4 knockdown. Further western blot assay confirmed these results (Fig. 5B) . Additionally, to further reveal the GTPBP4-p53 interaction in gastric cancer cells, co-IP analysis was performed with anti-GTPBP4 and anti-p53. As shown in Fig. 5C , GTPBP4 could bind to p53, while p53 could also bind to GTPBP4 in gastric cancer cells (Fig. 5D) . Importantly, GT-PBP4 expression was negatively correlated with p53 and its targets (TNFRSF10B, PTEN, CD-KN1A) expression (Fig. 5E -H) in gastric tumor tissues. Thus, we speculate that p53-related signaling might be involved in GTPBP4 functions. 
GTPBP4 promotes gastric cancer cell proliferation and inhibits cell apoptosis dependent on p53 expression
We sought to explore whether the GTPBP4-p53 interaction contributes to GTPBP4 functions in gastric cancer, rescue experiments were adopted to validate that p53 expression is imperative in GTPBP4-mediated promotion. P53 knockdown lentivirus vector (LV-p53-shRNA) was co-infected with LV-GTPBP4-shRNA in MKN45 and AGS cells. Western blot results showed that infection of LV-p53-shRNA significantly decreased p53 expression, and also attenuated GTPBP4 knockdown-induced increase of p53 expression in MKN45 and AGS cells (Fig. 6A) . As expected, decreased cell viability caused by GTPBP4 knockdown was attenuated or even reversed by p53 knockdown (Fig. 6B) . Moreover, p53 knockdown significantly restored the promotion of GTPBP4 knockdown on cell apoptosis (Fig. 6C) . Therefore, our results suggest that GTPBP4 promotes gastric cancer progression via binding to p53 and thus inhibiting p53-related signaling. 
GTPBP4 overexpression decreasescisplatin sensitivity in gastric cancer cells
We continued exploring whether GTPBP4 is involved in cisplatin sensitivity in gastric cancer cells. Firstly, we found that GTPBP4 level was significantly higher in SCG7901-DDP cells than that in SCG7901 cells (Fig. 7A) . And cisplatin-induced pro-apoptotic effect was attenuated by GTPBP4 overexpression (Fig.  7B) . Cisplatin-induced upregulation of cleavedcaspase3 and downregulation of Bcl-2 were attenuated by GTPBP4 overexpression (Fig. 7C) . Additionally, GTPBP4 knockdown weakened cisplatin resistance in SCG7901-DDP cells (Fig.  7D) . Therefore, our results demonstrate that GTPBP4 overexpression could confer cisplatin resistance in gastric cancer cells.
Discussion
GTPBPs could act as molecular switches to regulate various cellular process, like cell proliferation and cell cycle [15, 16] . GTPBP4, one of GTPBPs, is a GTPase that could be activated upon binding to GTP [17] . Previous studies have shown that GTPBP4 contributes to 60S ribosome biogenesis by its monomeric GTPase activity [10] . Furthermore, GTPBP4 could inhibit tumorigenic schwanomma cells proliferation via regulating merlin expression [17] . However, recent study has indicated that upregulation of GTPBP4 could promote colorectal cancer metastasis [11] . These results imply complex roles of GTPBP4 in tumor progression. And since the roles of GTPBP4 have not been revealed in gastric cancer, this study aims to explore the roles and related mechanisms of GTPBP4 in gastric cancer.
Here, we found that GTPBP4 expression was significantly increased in gastric tumor tissues compared with that in adjacent normal tissues, and positively correlated with gastric 
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Cellular Physiology and Biochemistry cancer stages, indicating that GTPBP4 could promote gastric tumor progression. Importantly, we found that GTPBP4 could interact with p53 and thus regulate the downstream negative effectors, which is in line with the previous study indicating that the GTPBP4-p53 interaction exists in lymphoblastoid cell lines and contributes to thiopurine resistance [8, 18] . However, the promotion of GTPBP4 on gastric cancer proliferation could not be abrogated, which means that other targets may be regulated by GTPBP4. As GTPBP4 exerts different functions in different cells, we conclude that the downstream signaling triggered by GTPBP4 might depend on the cell/tissue types. Importantly, it should be further explored whether the GTPBP4-p53 interaction is an universal phenomenon. Moreover, as both MKN45 and AGS cells have wild-type p53, we also examined the effect of GTPBP4 on the cell proliferation ability of SGC-7901 cells which has mutant p53, and consistent result was obtained (Fig.  8) , this result suggest that GTPBP4 might promote gastric cancer progression via another signaling independent p53-related pathway. The Rho family members RhoA and CDC42 are small GTPases that could modulate cell migration and actin cytoskeleton reorganization [19, 20] . Furthermore, inactivating Rho GTPase could prevent cell migration and cancer cells stemness [21, 22] . Notably, recent research has shown that Up-regulation of GTPBP4 in colorectal carcinoma is responsible for tumor metastasis, and GTPBP4 may disorganize actin cytoskeleton through repressing RhoA signaling [11] . Thus, the other functions and specific mechanisms underlying the effects of GTPBP4 on RhoA activity should be explored in the future. Notably, in the present study, our data just indicate the roles of GTPBP4 and its downstream potential effectors, further investigations could focus on revealing the upstream regulators of GTPBP4. Also, it must be noted that further in vivo experiments should be performed. Previous study has shown that GTPBP4 expression could distinguish potential endocrinedisrupting compounds in environmental samples [23] . To the best of our knowledge, this is the first study to investigate the roles of GTPBP4 in gastric cancer. Thus, GTPBP4 may be a novel therapeutic target for gastric patients.
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